Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP)
111-211
Phase 2 small_molecule active
Quick answer
Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP) for Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome is a Phase 2 program (small_molecule) at BioMarin International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioMarin International Limited
- Indication
- Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active